Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $615.76 | 7 | 99.0% |
| Education | $6.02 | 1 | 1.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $410.28 | 5 | $0 (2018) |
| Novo Nordisk Inc | $124.99 | 1 | $0 (2018) |
| PFIZER INC. | $73.57 | 1 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $12.94 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2018 | $332.44 | 4 | Janssen Pharmaceuticals, Inc ($194.51) |
| 2017 | $289.34 | 4 | Janssen Pharmaceuticals, Inc ($215.77) |
All Payment Transactions
8 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/10/2018 | AstraZeneca Pharmaceuticals LP | MOVANTIK (Drug) | Food and Beverage | In-kind items and services | $12.94 | General |
| Category: Neuroscience | ||||||
| 05/03/2018 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Diabetes | ||||||
| 04/06/2018 | Janssen Pharmaceuticals, Inc | INVOKANA (Drug) | Food and Beverage | In-kind items and services | $122.21 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 03/09/2018 | Janssen Pharmaceuticals, Inc | INVOKANA (Drug), INVOKAMET | Food and Beverage | In-kind items and services | $72.30 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 09/01/2017 | Janssen Pharmaceuticals, Inc | — | Education | In-kind items and services | $6.02 | General |
| 04/12/2017 | Janssen Pharmaceuticals, Inc | INVOKANA (Drug) | Food and Beverage | In-kind items and services | $124.75 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 01/31/2017 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $73.57 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 01/28/2017 | Janssen Pharmaceuticals, Inc | INVOKANA (Drug) | Food and Beverage | In-kind items and services | $85.00 | General |
| Category: Cardiovascular & Metabolism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 1,186 | 4,593 | $363,174 | $151,480 |
| 2022 | 15 | 1,025 | 3,902 | $322,641 | $142,238 |
| 2021 | 16 | 814 | 2,373 | $221,211 | $95,886 |
| 2020 | 16 | 975 | 2,362 | $240,855 | $90,722 |
All Medicare Procedures & Services
61 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 32 | 2,940 | $85,260 | $52,774 | 61.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 283 | 511 | $132,349 | $41,635 | 31.5% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 219 | 219 | $69,204 | $26,159 | 37.8% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 27 | 27 | $9,834 | $7,307 | 74.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 275 | 509 | $11,198 | $4,184 | 37.4% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 24 | 25 | $12,050 | $3,722 | 30.9% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 49 | 49 | $5,304 | $3,514 | 66.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 64 | 67 | $11,926 | $3,477 | 29.2% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2023 | 22 | 22 | $7,766 | $3,176 | 40.9% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 59 | 60 | $3,124 | $1,923 | 61.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 15 | 15 | $5,490 | $1,527 | 27.8% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 27 | 27 | $1,198 | $833.30 | 69.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 43 | 73 | $4,453 | $742.37 | 16.7% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 47 | 49 | $4,018 | $506.92 | 12.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 28 | 2,640 | $76,560 | $43,750 | 57.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 260 | 462 | $108,570 | $39,061 | 36.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 210 | 210 | $66,360 | $25,718 | 38.8% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2022 | 31 | 31 | $10,726 | $7,805 | 72.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 80 | 89 | $14,329 | $4,999 | 34.9% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 65 | 67 | $4,891 | $4,377 | 89.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 27 | 29 | $9,736 | $3,761 | 38.6% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2022 | 20 | 20 | $7,060 | $3,076 | 43.6% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 73 | 74 | $3,034 | $2,301 | 75.8% |
| 90732 | Pneumococcal vaccine, 23-valent | Office | 2022 | 17 | 17 | $2,788 | $2,260 | 81.1% |
| 99495 | Transitional care management services for problem of moderate complexity | Office | 2022 | 14 | 14 | $6,748 | $2,208 | 32.7% |
About Dr. Alexis Dunne, MD
Dr. Alexis Dunne, MD is a Internal Medicine healthcare provider based in Oswego, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/09/2008. The National Provider Identifier (NPI) number assigned to this provider is 1336324367.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alexis Dunne, MD has received a total of $621.78 in payments from pharmaceutical and medical device companies, with $332.44 received in 2018. These payments were reported across 8 transactions from 4 companies. The most common payment nature is "Food and Beverage" ($615.76).
As a Medicare-enrolled provider, Dunne has provided services to 4,000 Medicare beneficiaries, totaling 13,230 services with total Medicare billing of $480,327. Data is available for 4 years (2020–2023), covering 61 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Location Oswego, IL
- Active Since 01/09/2008
- Last Updated 07/09/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1336324367
Products in Payments
- INVOKANA (Drug) $404.26
- Ozempic (Drug) $124.99
- ELIQUIS (Drug) $73.57
- MOVANTIK (Drug) $12.94
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Oswego
Padma Ram, Md, MD
Internal Medicine — Payments: $13,097
Dr. Carlos Dator, Md, MD
Internal Medicine — Payments: $4,679
Dr. Carmen Bautista Dator, Md, MD
Internal Medicine — Payments: $4,005
Dr. Matthew Liepke, M.d, M.D
Internal Medicine — Payments: $3,419
David Bass, Do, DO
Internal Medicine — Payments: $1,150
Dr. Aaysha Kapila, M.d, M.D
Internal Medicine — Payments: $624.85